腫瘤壞死因子相關凋亡誘導配體(TRAIL)重組蛋白
Recombinant Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)
CD253; TNFSF10; APO2L; Apo2-L; TL2; TRAIL; Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand
- 編號RPA139Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位細胞膜
- 預測分子量35.9kDa
- 實際分子量37kDa(差異分析請參閱說明書)
- 片段與標簽Met40~Asn291 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 95%
- 等電點7.7
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1008 ¥ 2520 ¥ 5040 ¥ 15120 ¥ 37800
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure . Gene Sequencing (extract)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA139Mu01 | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA139Mu02 | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA139Mu01 | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA139Mu02 | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA139Mu71 | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| SEA139Mu | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| WEA139Mu | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)檢測試劑盒(酶聯(lián)免疫吸附試驗法,寬范圍) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA139Mu | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA139Mu01 | 腫瘤壞死因子相關凋亡誘導配體(TRAIL)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| PLOS ONE | Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model [Pubmed:25506835] |
| PLOS ONE | Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia [PubMed: 26633016] |
| Scientific Reports | Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice [pubmed:28507343] |
| Journal of Molecular Medicine | TRAIL and TRAIL Receptors as Prognostic Markers in Breast Cancer Patients [Pubmed: 31183506] |
| life sciences | Nifuroxazide attenuates experimentally-induced hepatic encephalopathy and the associated hyperammonemia and cJNk/caspase-8/TRAIL activation in rats [Pubmed: 32259601] |
| Int Immunopharmacol | Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling [Pubmed: 33199237] |
| ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY | Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathways [Pubmed: 32942000] |
| J Biochem Mol Toxicol | Tranilast abrogates cisplatin?\induced testicular and epididymal injuries: An insight into its modulatory impact on apoptosis/proliferation [34047436] |
留言咨詢
